An increasing number of adults in the United States are turning to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss, with drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) gaining widespread attention1 . These medications, originally developed for type 2 diabetes, have shown remarkable effects on weight reduction, offering new hope for managing obesity2 . Recent real-world studies reveal that Mounjaro may lead to significantly greater weight loss than Ozempic, highlighting important considerations for treatment choice3 .
Comparing Ozempic and Mounjaro
Ozempic and Mounjaro are both injectable medications primarily approved for type 2 diabetes management, but they differ in their mechanisms and weight loss efficacy4 . Ozempic contains semaglutide, a selective GLP-1 receptor agonist that mimics the hormone glucagon-like peptide-1 (GLP-1), which helps increase insulin secretion, slow gastric emptying, and reduce appetite4 . Mounjaro, on the other hand, contains tirzepatide, a dual agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, enhancing its weight loss effects through a combined hormonal action5 4.
This dual mechanism of Mounjaro is believed to underlie its superior efficacy in promoting weight loss compared to Ozempic, which targets only the GLP-1 pathway5 . Real-world data from a large retrospective cohort study of over 18,000 adults with overweight or obesity demonstrated that patients treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss milestones than those treated with semaglutide3 2. Specifically, tirzepatide users were:
- 1.8 times more likely to achieve at least 5% weight loss,
- 2.5 to 2.6 times more likely to achieve at least 10% weight loss,
- and 3 to 3.2 times more likely to achieve at least 15% weight loss within one year compared to semaglutide users3 2.
Weight loss differences were evident early and increased over time. At 3 months, tirzepatide users lost an average of 5.9% of body weight versus 3.6% for semaglutide users; at 6 months, 10.1% versus 5.8%; and at 12 months, 15.3% versus 8.3% 32. These findings were consistent across patients with and without type 2 diabetes, although those without diabetes generally experienced greater weight loss6 .
A phase 3b clinical trial comparing tirzepatide and semaglutide in adults with obesity but without diabetes also confirmed these results. After 72 weeks, tirzepatide recipients lost an average of 20.2% of their body weight compared to 13.7% with semaglutide7 . This trial used maximum tolerated doses of each drug, further supporting tirzepatide's superior efficacy.
| Parameter | Tirzepatide (Mounjaro) 37 | Semaglutide (Ozempic) 37 |
|---|---|---|
| Weight loss at 3 months | −5.9% to −6.0% | −3.6% to −3.7% |
| Weight loss at 6 months | −10.1% to −10.4% | −5.8% to −6.0% |
| Weight loss at 12 months | −15.3% to −20.2% | −8.3% to −13.7% |
| Likelihood of ≥15% weight loss | 3 times higher | Reference |
| Mechanism | Dual GLP-1 and GIP receptor agonist | GLP-1 receptor agonist only |
| Sources: 37 | ||
Despite these differences in efficacy, both drugs share similar gastrointestinal side effect profiles, including nausea, vomiting, diarrhea, and constipation5 4. These side effects are typically mild to moderate and tend to improve with dose titration8 9.
“I would agree that in this study Mounjaro has on average more weight loss than Ozempic. I would expect this as you have two satiety hormones versus one.”
— Ken Fujioka, MD, Scripps Clinic Nutrition and Metabolic Research Center10
Both Are Effective Treatment Options
Both Ozempic and Mounjaro represent significant advances in the management of obesity and type 2 diabetes, offering effective options for patients struggling with weight control11 12. GLP-1 receptor agonists like semaglutide and tirzepatide not only promote weight loss but also improve cardiometabolic risk factors such as blood glucose, blood pressure, and lipid profiles12 . These benefits extend beyond weight reduction, contributing to overall cardiovascular health13 .
However, real-world use of these medications reveals challenges related to medication access, insurance coverage, and patient adherence, which can influence treatment effectiveness14 15. Discontinuation rates are high for both drugs, with approximately 53% of patients stopping treatment within 12 months, often due to side effects, cost, or supply issues14 2. This highlights the importance of individualized treatment decisions that consider patient preferences, tolerability, and financial factors11 .
Common gastrointestinal adverse events reported with both drugs include nausea, vomiting, diarrhea, and constipation, but serious adverse events are rare8 5. Rates of moderate to severe gastrointestinal side effects are similar between tirzepatide and semaglutide, even though tirzepatide tends to produce greater weight loss3 2. Careful dose titration and patient monitoring can help mitigate these side effects9 .
Key considerations when selecting between Ozempic and Mounjaro include:
- Efficacy: Mounjaro generally leads to greater weight loss, especially at higher doses3 7.
- Side effects: Both drugs have similar gastrointestinal profiles, manageable with dose adjustments8 5.
- Cost and access: High medication costs and insurance coverage limitations can restrict use and adherence14 16.
- Patient factors: Comorbidities, treatment goals, and tolerability guide individualized therapy11 .
- Supply issues: Periodic shortages may affect availability and prescribing decisions14 2.
GLP-1 medications have already changed the way physicians treat type 2 diabetes and obesity, but little real-world data exist to compare the effectiveness of the two most common medications, Ozempic and Mounjaro.
2
Experts caution against viewing GLP-1 receptor agonists as a universal cure-all for obesity, emphasizing the need for comprehensive lifestyle interventions alongside pharmacotherapy13 . Additionally, the high cost of these medications poses a significant barrier to equitable access, prompting research into alternative weight maintenance strategies to optimize affordability without compromising clinical benefits16 .
